fashion -WSS

fashion

author：knowledge 2025-09-29 21:26:58 - browse：8733

The headquarter of Biotechnology company Ionis Pharmaceuticals, consists of glass windows, pale yellow exteriors and plants outside the building — biotech coverage from STAT — courtesy Ionis Pharmaceuticals

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for hereditary angioedema benefitted patients — including those taking drugs currently on the market.

In one of the Phase 3 trials, dubbed OASIS, patients with hereditary angioedema, a rare disease characterized by severe bouts of swelling, were given injections of donidalorsen either monthly or every two months. Those in the former group had an 81% lower monthly rate of swelling attacks after 25 weeks than patients given a placebo, while the reduction compared to placebo was 55% for those treated every two months.

The other study, OASISplus, found that donidalorsen’s benefits deepened and converged after up to an additional year of treatment, with swelling attack rates dropping by 92% to 93% regardless of how often patients were dosed. Notably, this study also tracked patients who switched over to donidalorsen from existing therapies meant to prevent swelling attacks, including drugs sold by Takeda and BioCryst Pharmaceuticals. Patients who switched to the Ionis drug saw their swelling attack rates drop by 62% compared to previous treatment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Democratic lawmaker calls for 'well

entertainment

WSS

Prime Medicine says its gene editing passes test in monkeys

Trump Jan. 6 attorney John Lauro is ex

How neuroscience research could help beat back brain cancer

3 dead in firefighting helicopter crash in California after midair collision with 2nd helicopter

What is microchimerism and how does it affect maternal health?

Infant mortality in U.S. rose last year for first time in decades: CDC

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Sports medicine is finally prioritizing gender equality

Live blog: Hearing on CRISPR

Wildfire smoke exposes gaps in outdoor worker protections

Prime Medicine says its gene editing passes test in monkeys

Cancer drug shortages should be causing more outrage

In Gaza, a nonprofit 3D prints tourniquets and stethoscopes

Virginia high school admissions case could be legal follow

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Prime Medicine says its gene editing passes test in monkeys

knowledge

Explaining an after

Thousands in Haiti march to demand safety from violent gangs as killings and kidnappings soar

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

Readout LOUD podcast: ESMO highlights & Roivant's big deal

hotspot

entertainment

entertainment

leisure time